The rule that comes first
Semaglutide is a peptide, and peptides are sensitive to heat, freezing and light. The FDA-approved Wegovy® label sets out precise storage rules for the branded pen, and they are a useful reference for what the molecule needs. But a compounded vial is a different product, prepared by a different pharmacy in a different container at a different concentration, and the rules that govern it are the ones on the label that pharmacy attaches to it. This guide puts the pharmacy label first, reports the branded label’s rules as the reference they are, and adds the two things the FDA says specifically about compounded GLP-1 products: what to do when a delivery arrives warm, and how long a multi-dose vial may be used.
This is general information and not medical advice. Personalized Compounded semaglutide, which Bodi Envi’s programs may include, is not FDA-approved and is not equivalent to Wegovy®. If anything about your medication’s storage is unclear, the pharmacy that prepared it is the right first call, and your care team can be messaged through the patient portal.
Read the pharmacy label
Your compounded medication arrives with a label from the pharmacy that prepared it. That label is the instruction sheet for your specific vial: how cold to keep it, whether and for how long it may be out of the refrigerator, how long it lasts once opened, how to handle an unused portion, and the pharmacy’s name and contact details. Every rule below defers to it. Where the pharmacy label and the branded label differ, the pharmacy label wins, because it describes the product in your hand and the branded label does not.
If the label is missing, damaged or unclear, do not guess. The FDA’s statement on unapproved GLP-1 drugs lists a product that arrives without instructions for use among the warning signs of an unsafe seller, and it advises patients to contact the compounder or the telehealth platform with any question about instructions for use or the label. Contact the pharmacy, and message your care team.
What the Wegovy® label says, for reference
The Wegovy® prescribing information gives the following storage rules for the branded single-dose pen and syringe. Store it in the refrigerator between 36°F and 46°F, which is 2°C to 8°C. Do not store it in the freezer or directly adjacent to the refrigerator’s cooling element. Do not freeze it, and do not use it if it has been frozen. Protect it from light and keep it in the original carton until the time of injection. Before the cap is removed, the pen or syringe may if needed be kept between 46°F and 86°F for up to 28 days. Discard the pen or syringe after use.
For the branded multi-dose pen, the label says to store it in the refrigerator before first use, and that after first use it may be kept for 56 days either at room temperature between 59°F and 86°F or in the refrigerator, protected from excessive heat and light, with the cap on and without a needle attached. The Zepbound® label gives similar rules for tirzepatide: refrigerate between 36°F and 46°F, do not freeze, protect from heat and light, and a single-dose pen or vial may be kept unrefrigerated at up to 86°F for a total of 21 days.
Three things in those rules carry over to any semaglutide product as a matter of chemistry: refrigeration is the normal state, freezing is disqualifying, and light and heat are to be avoided. The specific allowances, 28 days at room temperature before the cap is removed and 56 days after first use of the multi-dose pen, are properties of the branded products in their own packaging. They should not be assumed for a compounded vial. What your vial allows is on its label.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the FDA says about deliveries
The FDA’s statement dated September 1, 2026 addresses the moment the medication reaches your door. It says that injectable GLP-1 drugs require refrigeration as their package inserts indicate, that the agency has received complaints of compounded GLP-1 drugs arriving warm or with inadequate ice packs to keep them at the recommended storage temperature, and that it recommends patients not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration, because this can affect the drug’s quality.
So the first storage decision happens before the vial goes into the refrigerator. Check that the package is cold and the ice packs are intact. If the vial is warm to the touch, or the cold packs have thawed completely, do not use it; contact the pharmacy. Bodi Envi’s refund policy asks patients with a dispensing concern to contact the dispensing pharmacy promptly after delivery, using the contact details on the prescription label, and its shipping policy directs claims for packages damaged in transit to the carrier, with all packaging and damaged goods kept before filing. Your care team can be messaged through the patient portal for anything the pharmacy does not resolve.
Multi-dose vials and needles
The FDA’s statement also addresses vials that hold more than one dose, which is how personalized compounded semaglutide is often dispensed. It says that the agency generally recommends that vials containing multiple doses of sterile medications be used within 28 days after the first use, because there is an increased risk of contamination after that point. It notes that a patient may not finish a vial within 28 days, and its instruction is unambiguous: discard the vial within 28 days after the first use, even if medication remains, and do not continue using medication from the vial after 28 days even if the compounder’s instructions say it can be used for longer.
The same statement says to always use a new sterile needle and syringe for each dose, because reusing them can contaminate the medication. Both are rules about the medication after it has been opened, and they sit alongside the pharmacy label’s rules rather than replacing them. Where the pharmacy label gives a shorter period, follow the shorter.
Handling day to day
The practical routine that follows from the sources is short. Keep the vial in the refrigerator, in its carton or otherwise protected from light, away from the freezer compartment and the back wall where a refrigerator is coldest. Take it out only to draw up a dose, and return it. Look at the solution each time; the Wegovy® label says to use the medication only if it is clear, colorless and contains no particles, and the same standard is the sensible one for a vial. Write the date of first use on the carton so the 28 day rule is easy to keep. Use a new needle and syringe each time and dispose of them safely. And if the medication has been left out, has frozen, or has changed in appearance, contact the pharmacy before using it rather than after.
For travel, the guide on this site to travelling with tirzepatide covers the same questions for both molecules, including what the labels allow at room temperature and what the TSA says about medication at the airport.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the care team messaging is for
Bodi Envi’s programs include messaging with your care team through the patient portal. Storage questions that are about the medication itself belong first with the pharmacy that prepared it, whose details are on the prescription label. Questions about what to do next, whether a dose has been missed because a vial was unusable, or anything the pharmacy could not answer, belong with your care team. Bodi Envi is a LegitScript-certified U.S. telehealth platform and not a medical practice, pharmacy or medication manufacturer; it does not compound, dispense or ship medication itself, and third party U.S. 503A licensed compounding pharmacies do.
Personalized Compounded semaglutide is not FDA-approved and is not equivalent to Wegovy®. This guide is general information and not medical advice; the branded label’s rules are reported as a reference and the pharmacy label governs your vial; and your pharmacy and your provider are the people to ask.